The IMMP2L Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the human IMMP2L gene in the SK-HEP-1 host cell background. This product provides a genetically heterogeneous pool of cells with targeted gene disruption, enabling loss-of-function studies without clonal isolation. The polyclonal format preserves population-level diversity while abolishing IMMP2L expression, offering a robust model for investigating IMMP2L-dependent processes in a liver cancer context.
SK-HEP-1 is a well-characterized human hepatic adenocarcinoma cell line derived from the ascites of a patient with liver adenocarcinoma. These malignant cells exhibit an epithelial morphology and serve as a widely used in vitro model for hepatocellular carcinoma. Their tumorigenic origin and stable growth characteristics make them suitable for probing mitochondrial biology, metabolic reprogramming, and apoptosis in liver cancer. The SK-HEP-1 background therefore provides a clinically relevant platform to study IMMP2L function in a transformed hepatocyte setting.
IMMP2L encodes the catalytic subunit of the mitochondrial inner membrane peptidase (IMP) complex, which proteolytically removes sorting signals from nuclear-encoded precursor proteins after their import into mitochondria. IMMP2L functions as a heterodimer with its partner IMMP1L and acts downstream of the TOM and TIM23 translocase complexes. Its activity is essential for maturation of key substrates such as cytochrome c1 (CYC1) and DIABLO/SMAC. The gene is transcriptionally regulated by NRF1 and NRF2, linking its expression to mitochondrial biogenesis programs. Through these interactions, IMMP2L couples mitochondrial protein import to respiratory chain assembly and apoptotic signaling. Targeted disruption of IMMP2L therefore impairs processing of multiple precursor proteins, leading to accumulation of immature forms, defective oxidative phosphorylation, and altered apoptosis regulation.
Loss of IMMP2L in SK-HEP-1 cells generates a model of mitochondrial processing deficiency within a malignant hepatic environment. Because hepatocellular carcinoma cells rely on balanced mitochondrial function for proliferation, survival, and metabolic adaptation, IMMP2L knockout can expose vulnerabilities related to mitochondrial stress and apoptosis. This system allows dissection of how defects in the IMP complex influence liver cancer cell fitness, reactive oxygen species production, and apoptotic threshold. Furthermore, since IMMP2L dysfunction is implicated in neuropsychiatric disorders such as Tourette syndrome and autism spectrum disorder, this model permits cross-tissue mechanistic comparisons, even in a non-neuronal host, by focusing on conserved mitochondrial protein maturation pathways.
Typical applications include investigating mitochondrial proteostasis in hepatocellular carcinoma using Western blotting to monitor IMMP2L expression and cytochrome c1 processing, RT-qPCR for transcriptional profiling, and functional assays such as Seahorse-based mitochondrial respiration, cytochrome c oxidase activity measurements, and reactive oxygen species detection. Apoptosis can be assessed by Annexin V staining, and mitochondrial membrane potential evaluated with JC-1 dye. This knockout model is also suitable for genetic interaction screens and drug response studies targeting mitochondrial quality control in liver cancer. For additional information or to discuss custom applications, please contact Ascent Research.
